ArticleMultiple sclerosis and related disorders2024

A pilot trial of ocrelizumab for modulation of meningeal enhancement in multiple sclerosis.

Shishir Dahal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.